NCT05387265View on ClinicalTrials.gov

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions
Solid Tumors
Interventions
DRUG

CX-904

CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.

Trial Locations (5)

22031

Virginia Cancer Specialist, Fairfax

37203

Sarah Cannon Research Institute, LLC, Nashville

77030

MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

80218

Sarah Cannon Research Institute at HealthONE, Denver

Sponsors
All Listed Sponsors
lead

CytomX Therapeutics

INDUSTRY

NCT05387265 - A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter